Clin2
NCT07466498Possibly a fitNot yet recruiting

Estrogen for quality of life in men with advanced prostate cancer

Castration-Sensitive Prostate AdenocarcinomaMetastatic Castration-Sensitive Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8

Treatments studied

Part of Cancer, Kidney & urinary clinical trials.

This study tests whether estrogen patches can improve quality of life for men with prostate cancer that has spread but still responds to hormones. It compares adding estrogen to standard hormone therapy alone.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
60 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must have a diagnosis of prostate cancer that has spread (metastatic) and still responds to hormone therapy
  • You cannot have had chemotherapy for this type of prostate cancer before
  • You cannot have already taken certain hormone therapies like Lupron, Zytiga, or Xtandi (bicalutamide is okay)
  • You should not have a history of blood clots, heart attack, or stroke in the last 5 years
  • Your blood counts and organ function need to be within a safe range (checked by blood tests)
  • You must be willing to use effective birth control if sexually active

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06039371Recruiting· Phase 2
High dose testosterone during chemo for advanced prostate cancer

This trial tests if adding high doses of testosterone to standard chemotherapy (etoposide and carboplatin) can make the chemo work better in men whose prostate cancer has stopped responding to other treatments. It aims to see if this approach can shrink tumors or slow cancer growth.

Seattle, Washington
NCT06931340Recruiting· Phase 3
Adding chemo to hormone therapy for advanced prostate cancer

This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.

Tucson, Arizona
NCT03678025Recruiting· Phase 3
Standard treatment for metastatic prostate cancer, with or without local treatment

This Phase 3 trial studies whether using the usual medicines for metastatic prostate cancer, plus a definitive local treatment to the prostate, improves outcomes. It may help determine if treating the prostate directly can benefit people whose cancer has not worsened after initial hormone-based treatment.

Gilbert, Arizona
NCT06067269Recruiting· Phase 2
Hormone therapy and precise radiation for intermediate-risk prostate cancer

This trial tests whether giving a short course of hormone therapy (apalutamide) along with targeted, high-dose radiation (SBRT) is safe and effective for men with a specific type of intermediate-risk prostate cancer. You may benefit if you fit the exact risk and test criteria.

Los Angeles, California
NCT06271551Not yet recruiting· Phase 2
Estradiol patch and exercise to reduce side effects of hormone therapy for prostate cancer

This trial tests if wearing an estradiol patch and doing regular exercise can help lessen the side effects of standard hormone therapy (leuprorelin) given with radiation for prostate cancer.

NCT07143279Recruiting· Early Phase 1
Testosterone for quality of life in men with advanced cancer

This trial tests if testosterone supplements can improve quality of life for men with low testosterone who are no longer receiving active cancer treatment. It aims to help with symptoms like fatigue and low mood.

Brussels

Hear when a new Stage IVB Prostate Cancer AJCC v8 trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.